Celltrion Says New Data Prove Remsima SC Is A ‘Biobetter’

Subcutaneous Infliximab Shows Improved Outcomes Compared To Intravenous Version

 
• By Dave Wallace
  
Better word clouds
Celltrion’s subcutanous infliximab performed better than the intravenous version • Source: Shutterstock

More from Biosimilars

More from Products